Vericel Profile

USD 0.20  1.92%

Acquisition by Watling Sharon of 221000 shares of Vericel subject to Rule 16b-3

Vericel Corporation insider trading alert for grant of stock option (right to buy) by Watling Sharon, Vice President, on June 10, 2018. This event was filed by Vericel Corp with SEC on 2011-03-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Vericel Summary

Vericel Corporation (VCEL) is traded on Nasdaq Capital Markets in USA. It is located in 64 Sidney Street and employs 205 people. The company currently falls under 'Small-Cap' category with current market capitalization of 437.04 M. Vericel Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 42.43 M outstanding shares of which 1.98 M shares are at this time shorted by private and institutional investors with about 1.66 trading days to cover. Vericel Corporati currently holds about 29.78 M in cash with (9.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Vericel Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 10.6HorizonTargetOdds Above 10.6
77.09%30 days 10.60 22.74%
Based on normal probability distribution, the odds of Vericel to move above current price in 30 days from now is about 22.74% (This Vericel Corporation probability density function shows the probability of Vericel Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Essex Investment Management Co LlcCommon Shares97.2 K943 K
Bank Of MontrealCommon Shares39.8 K386 K
View Vericel Diagnostics

Vericel Risk Profiles

Key Fundamentals

Vericel Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Vericel Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts. Vericel operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 205 people. more
NameVericel Corporation
CEODominick ColangeloView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address64 Sidney Street
ExchangeNasdaq Capital Markets
IndustryPharmaceutical Products
Phone617 588 5555
CurrencyUSD - US Dollar

Vericel Corporate Directors

Alan Rubino Independent Director
Heidi Hagen Director
Steven Gilman Director
Also please take a look at World Market Map. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.